Pantherna´s scientific platform is based on two technological pillars, the PTXmRNA™ and PTX_LNP™, enabling optimized mRNA expression in the designated tissue for therapeutics purpose beyond vaccination. Novel PTX-mRNA-LNP are destined for transient expression of the desired therapeutic protein of interest via various administration routes. Current investigational development program PAN004 employs a three lipid moiety to generate pharmacologically distinct PTX-mRNA-LNP for the intravenous route to target exclusively the vascular endothelium of the lung.
Various novel PTX_LNP™ formulations are currently under development to address a broad spectrum of therapeutic applications. Because of this, we also team up with academic expert partners to investigate their suitability for a given medical condition. We are convinced that mRNA technologies will become a powerful pharmaceutical modality and we are striving to identify new potent mRNA therapeutics for diseases with high unmet medical need, including rare disease.
Next-generation PTX_LNP™ formulations for delivering PTXmRNA™ to various tissues and cell types
Formulations applicable for all different routes of administration
PTXcLNP™ enabling target protein expression in the vascular endothelium of the lung via the intravenous route
Modular lipid composition to generate novel LNPs
IP secured technology